Abstract: Pharmaceutical compositions for headache and pain relief comprising paraxanthine (1,7-dimethylxanthine) as an adjuvant analgesic enhancer combined with one or more analgesic agents selected from acetaminophen, aspirin, ibuprofen, naproxen, and naproxen sodium. Paraxanthine replaces caffeine as the xanthine adenosine receptor antagonist, providing analgesic potentiation via cerebral vasoconstriction while substantially reducing jitteriness, anxiety, and insomnia. Paraxanthine demonstrates up to 3.5×higher adenosine receptor potency than caffeine (A1 Ki 2.1×, A2A functional 3.5×) with 2.3×lower acute toxicity. Preferred embodiments: (A) paraxanthine 75 mg+acetaminophen 250 mg+aspirin 250 mg; (B) paraxanthine 75 mg+ibuprofen 200 mg; (C) paraxanthine 75 mg+naproxen sodium 220 mg; (D) paraxanthine 75 mg+ibuprofen 125 mg+acetaminophen 250 mg. Methods of treating headache pain with enhanced efficacy and reduced side effects are disclosed.

Abstract: A ready-to-drink carbonated beverage composition for cognitive enhancement comprising paraxanthine (1,7-dimethylxanthine, 100-500 mg) as an adenosine A1/A2A receptor antagonist, substantially free of caffeine; Alpha-GPC (100-600 mg) providing free choline for acetylcholine synthesis; citicoline (100-500 mg) providing cytidine for Kennedy pathway phosphatidylcholine membrane biosynthesis; taurine (500-2,000 mg) providing GABAergic modulation and osmoregulatory support; and a carbonation-stable spore-forming probiotic (Bacillus coagulans GBI-30, 6086, at least 500 million CFU) for gut-brain axis modulation. The five components simultaneously address adenosinergic, cholinergic-amplitude, cholinergic-structural, GABAergic/osmoregulatory, and gut-brain axes, producing bidirectional cognitive optimization. Preferred embodiments further comprise L-tyrosine, L-theanine, Panax ginseng extract, and vitamins in a zero-sugar 12-fluid-ounce carbonated beverage.